Efficacy
REMISSION, GCA
The mean length of exposure to JAKi was 19 (range 6−38) months. From the initiation of JAKi, significant reductions of CRP were seen at 3 (Longitudinal efficacy data from JAKi initiation (baseline) illustrated by No GCA relapses were observed during the observed time. At the 3-month follow-up, 9 of 15 (60%) subjects fulfilled our definition of therapeutic benefit. This percentage increased at the 6-month follow-up when 11 of 15 (73%) individuals fulfilled the outcome of therapeutic benefit. At the last follow-up, 12 of 15 (80%) patients were still on daily treatment with JAKi. Three patients had ceased due to sustained remission after having been on the drug for more than 2 years (range 26−29 months) (